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Background: Epidermal growth-factor receptor (EGFR) testing
and first-line therapy with gefitinib is becoming the standard
treatment for advanced non-small-cell lung cancer (NSCLC). Yet,
to date, no study has quantified the cost-effectiveness of this
approach within an Asian population, where the prevalence of
activating mutations is higher than among western populations.
Methods: A decision-analytic model was developed to deter-
mine the cost-effectiveness of EGFR testing and first-line treat-
ment with gefitinib for patients with activating EGFR mutations,
versus standard care, which includes first-line treatment with
chemotherapy followed by gefitinib as second-line treatment.
The model uses clinical and outcomes data from three random-
ised clinical trials, and societal (non-subsidised) costs from three
cancer treatment centres in Singapore. Health effects were
expressed as quality-adjusted life-years (QALY) gained. Costs
include relevant costs for prescription medications, physician vis-
its, laboratory tests, scans, hospitalisations, and treatment of
adverse events. All costs and cost-effectiveness ratios were
expressed in 2010 Singapore dollars. Sensitivity analyses were
done to identify the extent to which results were robust to key
model assumptions.
Findings: EGFR testing and first-line treatment with gefitinib
was found to be a dominant strategy (lower costs and greater
effectiveness) compared with standard care. Because the primary
savings in the testing group did not result from not providing
gefitinib to patients who do not benefit, this finding holds regard-
less of the percentage of patients who test positive for EGFR
mutation. In a secondary analysis, first-line treatment with gefiti-
nib was also dominant compared with first-line chemotherapy in
patients with activating EGFR mutations.
Interpretation: Based on these data, EGFR testing and first-line
treatment with gefitinib for patients with activating mutations
should become a standard treatment in advanced NSLC.
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Background: Neuroblastoma is the most common extracranial
tumour, accounting for 8–10% of childhood malignancies and
15% of deaths from cancer in the paediatric age group. Approxi-
mately half of newly diagnosed children are at high risk for
treatment failure. The aim of this study was to evaluate the
response rate of salvage chemotherapy with ifosfamide, carbo-
platin, and etoposide (ICE) when given to previously treated
patients with primary refractory or progressive high-risk
neuroblastoma.
Methods: Sixty-six patients from NCI and CCHE received sal-
vage chemotherapy (ICE) for primary resistance (n = 51, 77.2%)
or disease progression on primary chemotherapy (n = 15 22.8%).
Forty male patients (60.6%) and 26 females (39.4%), between 3
months and 12.5 years of age, were included.
Findings: The most common tumour site was suprarenal, fol-
lowed by retroperitoneal mass. Two patients (3%) died from che-
motherapy toxicity during ICE administration. Evaluation of
tumour response in the remaining 64 patients showed the follow-
ing: complete or partial response in 24 patients (36.5%), stable
disease in 11 patients (16.6%), and progressive disease in 29
patients (43.9%). 14 patients (21.2%) were considered eligible for
an autologous bone-marrow transplant, and 50 patients (78.8%)
failed second-line (salvage) chemotherapy and had palliative
lines of therapy. By the end of the study (May 2010), 47 of 66
(71.2%) of patients were still alive, and 19 of 66 (28.8%) were dead.
Two of 14 patients (14.2%) who underwent haematopoietic stem-
cell transplantation died from post-transplantation disease pro-
gression, and 12 of 14 (85.8%) were in complete cytogenic remis-
sion (CCR).
Interpretation: Chemotherapy with ICE for primary resistant or
progressive stage III–IV neuroblastoma seemswell tolerated. With
a 36.6% response rate, 18% CCR, and 3.0% treatment mortality
rate, it can be considered a good salvage therapy for patients in
whom palliation is appropriate.
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Background: The aim of this study was to compare oestrogen-
receptor (ER) and progesterone-receptor (PgR) status of operable
breast cancers in Vietnamese and Swedish patients.
Methods: Primary breast-cancer tissues were randomly
selected from 249 Vietnamese patients treated in Hanoi, Vietnam,
and 1257 Swedish patients treated in Stockholm, Sweden,
between 2002 and 2003. Clinical information was available for
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